1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Jointown Pharmaceutical Group Co., Ltd
  6. News
  7. Summary
    600998   CNE100000W45

JOINTOWN PHARMACEUTICAL GROUP CO., LTD

(600998)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Jointown Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021

04/26/2021 EDT

Jointown Pharmaceutical Group Co., Ltd. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced total revenue was CNY 32,628.931 million compared to CNY 27,173.057 million a year ago. Operating income was CNY 1,025.006 million compared to CNY 784.142 million a year ago. Net income was CNY 760.015 million compared to CNY 576.967 million a year ago. Basic earnings per share from continuing operations was CNY 0.4 compared to CNY 0.29 a year ago. Diluted earnings per share from continuing operations was CNY 0.39 compared to CNY 0.28 a year ago.


© S&P Capital IQ 2021
All news about JOINTOWN PHARMACEUTICAL GROUP CO., LTD
04/26Jointown Pharmaceutical Group Co., Ltd announces an Equity Buyback for CNY 600 million ..
CI
04/26Jointown Pharmaceutical Group Co., Ltd authorizes a Buyback Plan.
CI
04/25Jointown Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended..
CI
04/25Jointown Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter E..
CI
04/18Binhui Biopharm announced that it has received $47.1 million in funding from Yangtze Ri..
CI
2021Jointown Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months En..
CI
2021Jointown Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ende..
CI
2021Jointown Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter ..
CI
2021Tranche Update on Jointown Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announc..
CI
2021Jointown Pharmaceutical Group Co., Ltd.'s Equity Buyback announced on September 16, 202..
CI
More news
Financials
Sales 2022 138 B 20 657 M 20 657 M
Net income 2022 2 369 M 354 M 354 M
Net Debt 2022 8 880 M 1 327 M 1 327 M
P/E ratio 2022 9,70x
Yield 2022 2,86%
Capitalization 22 595 M 3 376 M 3 376 M
EV / Sales 2022 0,23x
EV / Sales 2023 0,20x
Nbr of Employees 29 338
Free-Float 36,1%
Chart JOINTOWN PHARMACEUTICAL GROUP CO., LTD
Duration : Period :
Jointown Pharmaceutical Group Co., Ltd Technical Analysis Chart | 600998 | CNE100000W45 | MarketScreener
Technical analysis trends JOINTOWN PHARMACEUTICAL GROUP CO., LTD
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Last Close Price 12,25 CNY
Average target price 13,40 CNY
Spread / Average Target 9,39%
EPS Revisions
Managers and Directors
Wei He General Manager
Ying Zheng Xu Member-Supervisory Board & Chief Accountant
Xu Min Wen Director
Chang Yun Liu Chairman
Qi Ming Chen Director & Deputy General Manager-Investment
Sector and Competitors
1st jan.Capi. (M$)
JOINTOWN PHARMACEUTICAL GROUP CO., LTD-16.78%3 334
JOHNSON & JOHNSON1.68%457 706
PFIZER, INC.-11.14%284 192
ABBVIE INC.11.53%268 106
ROCHE HOLDING AG-16.41%265 188
ELI LILLY AND COMPANY8.19%257 689